Photo: Katherine Frey/The Washington Post via Getty Images

The Food and Drug Administration said it will continue to regulate hemp products that contain "cannabis or cannabis-derived compounds" despite President Trump legalizing the production and marketing of industrial hemp under the farm bill signed Thursday.

The big picture: The hemp-derived and non-psychoactive compound cannabidiol, or CBD oil, has previously been approved by the FDA for the treatment of two forms of epilepsy. But its increasing popularity as an ingredient in lotions, dietary supplements and other medicinal applications has thrust it into murky legal territory, with the FDA ruling that, like any illegal substance, it will remain subject to regulation.

Go deeper: Great green hope — The big picture on legal marijuana

Go deeper

FDA approves Gilead's remdesivir as a coronavirus treatment

A production line of Remdesivir. Photo: Fadel Dawood/picture alliance via Getty Images

Gilead Sciences on Thursday received approval from the Food and Drug Administration for remdesivir, an antiviral treatment that has shown modest results against treating COVID-19.

Why it matters: It's the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.

How the coronavirus pandemic could end

Illustration: Sarah Grillo/Axios

It's still the early days of the coronavirus pandemic, but history, biology and the knowledge gained from our first nine months with COVID-19 point to how the pandemic might end.

The big picture: Pandemics don't last forever. But when they end, it usually isn't because a virus disappears or is eliminated. Instead, they can settle into a population, becoming a constant background presence that occasionally flares up in local outbreaks.

Urban housing prices are on the rise

Data: ATTOM Data Solutions; Chart: Naema Ahmed/Axios

Home prices are rising rapidly across the U.S., according to ATTOM Data Solutions.

Driving the news: ATTOM released its 3Q 2020 figures this week, concluding that 77% of metro areas posted "double-digit annual home price gains." Profit margins rose in 86% of the 103 metropolitan statistical areas studied.